The first 3 subjects will be assigned to Expansion Cohort 2.1 (EC2.1) and will receive PV-10 administered at 0.25 mL PV-10 per cc Lv (up to a maximum dose of 7.5 mL PV-10). If none of the initial 3 subjects experiences dose-limiting toxicity (DLT), defined as onset of any Grade 3 or greater non-hematological (excluding fatigue) or Grade 4 hematological toxicity within 28 days of PV-10 administration that is persistent for 14 days or longer, enrollment in Expansion Cohort 2.2 will commence. If 2 or more of the initial 3 subjects experience a DLT, the combination of PV-10 and sorafenib at this PV-10 dose level will be judged to be intolerable. If one of the initial 3 subjects experiences a DLT, an additional 3 subjects will be enrolled in Expansion Cohort 2.1. If none of these additional subjects experiences a DLT, enrollment in Expansion Cohort 2.2 will commence. If 1 or more of the 3 additional subjects (i.e., ≥ 2 of 6 subjects) experiences a DLT, the combination of PV-10 and sorafenib at this PV-10 dose level will be judged to be intolerable.